Jelle E. Bousema
Research Subjects
Jelle E. Bousema has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Frank Jozef Christiaan van Den Broek
Department of Surgery, Máxima Medical Center, Veldhoven, The Netherlands
5 shared publications - Jouke Tabe Annema
Department of Respiratory Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
3 shared publications - Marcel G. W. Dijkgraaf
Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands
3 shared publications - Jos. G. Maessen
Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre , P.Debyelaan, 12, Maastricht, 6221 AZ, The
2 shared publications - Niels J. M. Claessens
Department of Respiratory Medicine, Rijnstate ziekenhuis, Arnhem, The Netherlands
2 shared publications - Wilhelmina H. Schreurs
Department of Surgery, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands
2 shared publications
Latest Publications
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4683
Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (MEDIASTrial)
Resectable non-small cell lung cancer (NSCLC) with increased risk of mediastinal nodal involvement requires invasive staging prior to surgical lung tumor resection. The MEDIASTrial demonstrated that the omission of confirmatory mediastinoscopy after negative systematic endosonography led to a clinically negligible and non-inferior increase in unforeseen N2 of 1.0%. We report the 2-year overall and disease-free survival (OS and DFS) and the health-related quality of life (HRQoL). The MEDIASTrial was a non-inferiority trial including patients with resectable NSCLC after negative endosonography. Patients were randomized to either immediate resection (n=178) or to mediastinoscopy first (n=182), only followed by resection in case of negative mediastinoscopy. OS is defined from randomisation until death from any cause; and DFS until cancer relapse or death from any cause. Two-year OS and DFS are reported as percentages with odds ratios (ORs) with 95%-confidence intervals (95-CI). The HRQoL was gathered with the QLQ-C30 (general) and QLQ-LC13 (lung cancer specific) questionnaires. After randomisation 7 drop-outs were observed in both groups. Two-year OS was 80% (136/171) in the immediate resection group versus 77% (134/175) in the mediastinoscopy group (OR 0.8, 95%-CI: 0.5-1.4), and 2-year DFS was 60% (102/171) versus 60% (105/175) respectively (OR 1.0, 95%-CI: 0.7-1.6). The HRQoL scores were comparable among the groups during the 2-year follow-up. The loss in diagnostic yield by omitting confirmatory mediastinoscopy after negative systematic endosonography has no impact on 2-year OS, DFS and HRQoL.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA4683
Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (MEDIASTrial)
Resectable non-small cell lung cancer (NSCLC) with increased risk of mediastinal nodal involvement requires invasive staging prior to surgical lung tumor resection. The MEDIASTrial demonstrated that the omission of confirmatory mediastinoscopy after negative systematic endosonography led to a clinically negligible and non-inferior increase in unforeseen N2 of 1.0%. We report the 2-year overall and disease-free survival (OS and DFS) and the health-related quality of life (HRQoL). The MEDIASTrial was a non-inferiority trial including patients with resectable NSCLC after negative endosonography. Patients were randomized to either immediate resection (n=178) or to mediastinoscopy first (n=182), only followed by resection in case of negative mediastinoscopy. OS is defined from randomisation until death from any cause; and DFS until cancer relapse or death from any cause. Two-year OS and DFS are reported as percentages with odds ratios (ORs) with 95%-confidence intervals (95-CI). The HRQoL was gathered with the QLQ-C30 (general) and QLQ-LC13 (lung cancer specific) questionnaires. After randomisation 7 drop-outs were observed in both groups. Two-year OS was 80% (136/171) in the immediate resection group versus 77% (134/175) in the mediastinoscopy group (OR 0.8, 95%-CI: 0.5-1.4), and 2-year DFS was 60% (102/171) versus 60% (105/175) respectively (OR 1.0, 95%-CI: 0.7-1.6). The HRQoL scores were comparable among the groups during the 2-year follow-up. The loss in diagnostic yield by omitting confirmatory mediastinoscopy after negative systematic endosonography has no impact on 2-year OS, DFS and HRQoL.
- Open Access
- 27 February 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-13
MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan
Background: Invasive mediastinal nodal staging is recommended by guidelines in selected patients with resectable non-small cell lung cancer (NSCLC). Endosonography is recommended as initial staging technique, followed by confirmatory mediastinoscopy in case of negative N2 or N3 cytology after endosonography. Confirmatory mediastinoscopy however is under debate owing its limited additional diagnostic value, its associated morbidity and its delay in the start of lung cancer treatment. The MEDIASTrial examines whether confirmatory mediastinoscopy can be safely omitted after negative endosonography in mediastinal nodal staging of NSCLC. The present work is the proposed statistical analysis plan of the clinical consequences of omitting mediastinoscopy, which is submitted before closure of the MEDIASTrial and before knowledge of any results was done to enhance transparency of scientific behaviour.Methods: The primary outcome measure of this non-inferiority trial will be unforeseen N2 disease resulting from lobe-specific mediastinal lymph node dissection. For non-inferiority, the upper limit of the 95% confidence interval of the unforeseen N2 rate in the group without mediastinoscopy should not exceed 14.3% in order to probably have no negative impact on survival. Since this is a non-inferiority trial, both an intention to treat (ITT) and a per protocol (PP) analyses will be done. The ITT and the PP analyses should both indicate non-inferiority before the diagnostic strategy omitting mediastinoscopy will be interpreted as non-inferior to the strategy with mediastinoscopy. Secondary outcome measures include 30-day major morbidity and mortality, the total number of days of hospital care, overall and disease free 2-year survival, generic and disease-specific health related quality of life and cost-effectiveness and cost-utility of staging strategies with and without mediastinoscopy.Discussion: The MEDIASTrial will determine if confirmatory mediastinoscopy can be omitted after tumour negative systematic endosonography in invasive mediastinal staging of patients with resectable NSCLC.Trial registration: Netherlands Trial RegisterNL6344/NTR6528. Registered on 2017 July 06
- 27 February 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-13
Open AccessMEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan
Background: Invasive mediastinal nodal staging is recommended by guidelines in selected patients with resectable non-small cell lung cancer (NSCLC). Endosonography is recommended as initial staging technique, followed by confirmatory mediastinoscopy in case of negative N2 or N3 cytology after endosonography. Confirmatory mediastinoscopy however is under debate owing its limited additional diagnostic value, its associated morbidity and its delay in the start of lung cancer treatment. The MEDIASTrial examines whether confirmatory mediastinoscopy can be safely omitted after negative endosonography in mediastinal nodal staging of NSCLC. The present work is the proposed statistical analysis plan of the clinical consequences of omitting mediastinoscopy, which is submitted before closure of the MEDIASTrial and before knowledge of any results was done to enhance transparency of scientific behaviour.Methods: The primary outcome measure of this non-inferiority trial will be unforeseen N2 disease resulting from lobe-specific mediastinal lymph node dissection. For non-inferiority, the upper limit of the 95% confidence interval of the unforeseen N2 rate in the group without mediastinoscopy should not exceed 14.3% in order to probably have no negative impact on survival. Since this is a non-inferiority trial, both an intention to treat (ITT) and a per protocol (PP) analyses will be done. The ITT and the PP analyses should both indicate non-inferiority before the diagnostic strategy omitting mediastinoscopy will be interpreted as non-inferior to the strategy with mediastinoscopy. Secondary outcome measures include 30-day major morbidity and mortality, the total number of days of hospital care, overall and disease free 2-year survival, generic and disease-specific health related quality of life and cost-effectiveness and cost-utility of staging strategies with and without mediastinoscopy.Discussion: The MEDIASTrial will determine if confirmatory mediastinoscopy can be omitted after tumour negative systematic endosonography in invasive mediastinal staging of patients with resectable NSCLC.Trial registration: Netherlands Trial RegisterNL6344/NTR6528. Registered on 2017 July 06
- Open Access
- 22 October 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1-8
Subpleural multilevel intercostal continuous analgesia after thoracoscopic pulmonary resection: a pilot study
Background: Sufficient pain control and rapid mobilisation after VATS are important to enhance recovery and prevent complications. Thoracic epidural analgesia (TEA) is the gold standard, but failure rates of 9–30% have been described. In addition, TEA reduces patient mobilisation and bladder function. Subpleural continuous analgesia (SCA) is a regional analgesic technique that is placed under direct thoracoscopic vision and is not associated with the mentioned disadvantages of TEA. The objective of this study was to assess surgical feasibility, pain control and patient satisfaction of SCA.Methods: Observational pilot study in patients who underwent VATS pulmonary resection and received SCA (n = 23). Pain scores (numeric rating scale 0–10) and patient satisfaction (5-point Likert scale) were collected on postoperative day (POD) 0–3. Secondary outcomes were the period of urinary catheter use and period to full mobilisation.Results: Placement of the subpleural catheter took an average of 11 min (SD 5) and was successful in all patients. Pain scores on POD 0–3 were 1.2 (SD 1.2), 2.0 (SD 1.9), 1.7 (SD 1.5) and 1.2 (SD 1.1) respectively. On POD 0–3 at least 79% of patients were satisfied or very satisfied on pain relief and mobilisation. The duration of subpleural continuous analgesia was 4 days (IQR 3–5, range 2–11). Urinary catheters were used zero days (IQR 0–1, range 0–6) and full mobilisation was achieved on POD 2 (IQR 1–2, range 1–6).Conclusion: Subpleural continuous analgesia in VATS pulmonary resection is feasible and provides adequate pain control and good patient satisfaction.Trial registration: This pilot study was not registered in a trial register.
- 22 October 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1-8
Open AccessSubpleural multilevel intercostal continuous analgesia after thoracoscopic pulmonary resection: a pilot study
Background: Sufficient pain control and rapid mobilisation after VATS are important to enhance recovery and prevent complications. Thoracic epidural analgesia (TEA) is the gold standard, but failure rates of 9–30% have been described. In addition, TEA reduces patient mobilisation and bladder function. Subpleural continuous analgesia (SCA) is a regional analgesic technique that is placed under direct thoracoscopic vision and is not associated with the mentioned disadvantages of TEA. The objective of this study was to assess surgical feasibility, pain control and patient satisfaction of SCA.Methods: Observational pilot study in patients who underwent VATS pulmonary resection and received SCA (n = 23). Pain scores (numeric rating scale 0–10) and patient satisfaction (5-point Likert scale) were collected on postoperative day (POD) 0–3. Secondary outcomes were the period of urinary catheter use and period to full mobilisation.Results: Placement of the subpleural catheter took an average of 11 min (SD 5) and was successful in all patients. Pain scores on POD 0–3 were 1.2 (SD 1.2), 2.0 (SD 1.9), 1.7 (SD 1.5) and 1.2 (SD 1.1) respectively. On POD 0–3 at least 79% of patients were satisfied or very satisfied on pain relief and mobilisation. The duration of subpleural continuous analgesia was 4 days (IQR 3–5, range 2–11). Urinary catheters were used zero days (IQR 0–1, range 0–6) and full mobilisation was achieved on POD 2 (IQR 1–2, range 1–6).Conclusion: Subpleural continuous analgesia in VATS pulmonary resection is feasible and provides adequate pain control and good patient satisfaction.Trial registration: This pilot study was not registered in a trial register.
- 1 August 2019
- Published by Elsevier in Lung Cancer
- Vol. 134, 52-58
Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis
- 1 August 2019
- Published by Elsevier in Lung Cancer
- Vol. 134, 52-58
Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis
- Open Access
- 18 May 2018
- Published by Springer Nature in BMC Surgery
- Vol. 18 (1) , 1-11
MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial
Background: In case of suspicious lymph nodes on computed tomography (CT) or fluorodeoxyglucose positron emission tomography (FDG-PET), advanced tumour size or central tumour location in patients with suspected non-small cell lung cancer (NSCLC), Dutch and European guidelines recommend mediastinal staging by endosonography (endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)) with sampling of mediastinal lymph nodes. If biopsy results from endosonography turn out negative, additional surgical staging of the mediastinum by mediastinoscopy is advised to prevent unnecessary lung resection due to false negative endosonography findings. We hypothesize that omitting mediastinoscopy after negative endosonography in mediastinal staging of NSCLC does not result in an unacceptable percentage of unforeseen N2 disease at surgical resection. In addition, omitting mediastinoscopy comprises no extra waiting time until definite surgery, omits one extra general anaesthesia and hospital admission, and may be associated with lower morbidity and comparable survival. Therefore, this strategy may reduce health care costs and increase quality of life. The aim of this study is to compare the cost-effectiveness and cost-utility of mediastinal staging strategies including and excluding mediastinoscopy. Methods/design: This study is a multicenter parallel randomized non-inferiority trial comparing two diagnostic strategies (with or without mediastinoscopy) for mediastinal staging in 360 patients with suspected resectable NSCLC. Patients are eligible for inclusion when they underwent systematic endosonography to evaluate mediastinal lymph nodes including tissue sampling with negative endosonography results. Patients will not be eligible for inclusion when PET/CT demonstrates ‘bulky N2-N3’ disease or the combination of a highly suspicious as well as irresectable mediastinal lymph node. Primary outcome measure for non-inferiority is the proportion of patients with unforeseen N2 disease at surgery. Secondary outcome measures are hospitalization, morbidity, overall 2-year survival, quality of life, cost-effectiveness and cost-utility. Patients will be followed up 2 years after start of treatment. Discussion: Results of the MEDIASTrial will have immediate impact on national and international guidelines, which are accessible to public, possibly reducing mediastinoscopy as a commonly performed invasive procedure for NSCLC staging and diminishing variation in clinical practice. Trial registration: The trial is registered at the Netherlands Trial Register on July 6th, 2017 (NTR 6528).
- 18 May 2018
- Published by Springer Nature in BMC Surgery
- Vol. 18 (1) , 1-11
Open AccessMEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial
Background: In case of suspicious lymph nodes on computed tomography (CT) or fluorodeoxyglucose positron emission tomography (FDG-PET), advanced tumour size or central tumour location in patients with suspected non-small cell lung cancer (NSCLC), Dutch and European guidelines recommend mediastinal staging by endosonography (endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)) with sampling of mediastinal lymph nodes. If biopsy results from endosonography turn out negative, additional surgical staging of the mediastinum by mediastinoscopy is advised to prevent unnecessary lung resection due to false negative endosonography findings. We hypothesize that omitting mediastinoscopy after negative endosonography in mediastinal staging of NSCLC does not result in an unacceptable percentage of unforeseen N2 disease at surgical resection. In addition, omitting mediastinoscopy comprises no extra waiting time until definite surgery, omits one extra general anaesthesia and hospital admission, and may be associated with lower morbidity and comparable survival. Therefore, this strategy may reduce health care costs and increase quality of life. The aim of this study is to compare the cost-effectiveness and cost-utility of mediastinal staging strategies including and excluding mediastinoscopy. Methods/design: This study is a multicenter parallel randomized non-inferiority trial comparing two diagnostic strategies (with or without mediastinoscopy) for mediastinal staging in 360 patients with suspected resectable NSCLC. Patients are eligible for inclusion when they underwent systematic endosonography to evaluate mediastinal lymph nodes including tissue sampling with negative endosonography results. Patients will not be eligible for inclusion when PET/CT demonstrates ‘bulky N2-N3’ disease or the combination of a highly suspicious as well as irresectable mediastinal lymph node. Primary outcome measure for non-inferiority is the proportion of patients with unforeseen N2 disease at surgery. Secondary outcome measures are hospitalization, morbidity, overall 2-year survival, quality of life, cost-effectiveness and cost-utility. Patients will be followed up 2 years after start of treatment. Discussion: Results of the MEDIASTrial will have immediate impact on national and international guidelines, which are accessible to public, possibly reducing mediastinoscopy as a commonly performed invasive procedure for NSCLC staging and diminishing variation in clinical practice. Trial registration: The trial is registered at the Netherlands Trial Register on July 6th, 2017 (NTR 6528).